A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 18 years * Metastatic melanoma (Stage IV) * Histologically confirmed malignant melanoma with measurable or non-measurable disease * Ability and willingness to comply with study and follow-up procedures Exclusion Criteria: * Prior treatment for Stage IV disease with chemotherapy or biologic therapy such as interferon and interleukin-2 * Complete surgical resection or irradiation of all identifiable sites of disease at randomization * Radiation therapy within 14 days prior to Day 1 * Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy * Melanoma of ocular origin * Known central nervous system (CNS) disease/brain metastases (history of brain disease or active disease) * Life expectancy of \< 12 weeks * Current, recent, or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study * Inadequate organ function * History of other malignancies within 5 years of Day 1, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications * Inadequately controlled hypertension * History of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Class II or greater CHF * History of myocardial infarction or unstable angina within 6 months prior to Day 1 * History of stroke or transient ischemic attack within 6 months prior to Day 1 * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 * History of hemoptysis within 1 month prior to Day 1 * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 * History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 * Serious, non-healing wound, active ulcer, or untreated bone fracture * Known hypersensitivity to any component of bevacizumab * Pregnancy (positive pregnancy test) or lactation * Current, ongoing treatment with full-dose warfarin